| AXON
Ceftriaxone Sodium

Description:
Axon is
a third generation broad-spectrum parenteral cephalosporin antibiotic.
It has potent bactericidal activity against a wide range of
Gram-positive and Gram-negative organisms. Axon like
other cephalosporins and penicillins kills bacteria by interfering
with the synthesis of the bacterial cell wall. Axon has
a high degree of stability in the presence of beta lactamases.
A remarkable feature of Axon is its relatively long plasma
elimination half-life of about 6 to 9 hours, which makes single
or once-daily dosage of the drug appropriate for most patients.
Ceftriaxone is not metabolized in the body. About 40-65% of
a dose of Ceftriaxone is excreted unchanged in the urine; the
remainder is excreted in the bile and ultimately found in the
feces as unchanged drug and microbiologically inactive compound.
The drug is highly protein bound (95%).
Composition:
Axon 250
mg IM/IV Injection: Each vial contains dry powder equivalent
to 250 mg Ceftriaxone (as sterile Ceftriaxone Sodium USP) and
1 ampoule of 2 ml 1% Lidocaine Injection USP for IM injection
or 5 ml Water for Injection BP for IV injection.
Axon 500
mg IM/IV Injection: Each vial contains dry powder equivalent
to 500 mg ceftriaxone (as sterile Ceftriaxone Sodium USP) and
1 ampoule of 2 ml 1% Lidocaine Injection USP for IM injection
or 5 ml Water for Injection BP for IV injection.
Axon 1
g IM/IV Injection: Each vial contains dry powder equivalent
to 1 g Ceftriaxone (as sterile Ceftriaxone Sodium USP)
and 1 ampoule of 3.5 ml Lidocaine 1% Injection USP for IM injection
or 10 ml Water for Injection BP for IV injection.
Axon 2 g IV
Injection: Each vial contains dry powder equivalent to 2g
Ceftriaxone (as sterile Ceftriaxone Sodium USP) and 2 ampules
of 10 ml water for injection BP for IV injection.
Indications:
Axon is
indicated for the treatment of the following major infections:
1. Renal and urinary tract Infections 2. Lower respiratory tract
infections, particularly pneumonia 3. Gonococcal infections
4. Skin soft tissue, bone and joint infections 5. Bacterial
meningitis 6. Serious bacterial infections e.g. septicemia
7. ENT infections 8. Infections in cancer patients 9. Prevention
of postoperative infections 10. Perioperative prophylaxis of
infections associated with surgery 11. Typhoid fever.
Dosage &
Administration:
Adult: by
deep intramuscular injection, or by intravenous injection over
at least 2-4 minutes, or by intravenous infusion, 1 g daily;
2-4 g daily in severe infections; intramuscular doses over 1
g divided between more than one site. Neonate: by intravenous
infusion over 60 minutes, 20-50 mg/kg daily (max.50 mg/kg daily).
Infant and child under 50 kg: by deep intramuscular injection
or by intravenous injection over 2-4 minutes or by intravenous
infusion, 20-50 mg/kg daily; up to 80 mg/kg daily in severe
infections; doses of 50 mg/kg and over by intravenous infusion
only; 50 kg and over, adult dose. Uncomplicated gonorrhea:
by deep intramuscular injection, 250 mg as a single dose. Surgical
prophylaxis: by deep intramuscular injection or by intravenous
injection over at least 2-4 minutes, 1 g at induction, Colorectal
surgery: by deep intramuscular injection or by intravenous
injection over at least 2-4 minutes or by intravenous infusion,
2 g at induction; intramuscular doses over 1 g divided between
more than one site.
Duration of
Therapy:
Continue for ≥ 2 days after signs and symptoms of infection
have disappeared. Usual duration is 4 to 14 days; in complicated
infections, longer therapy may be required.
Preparation
of Solutions for Intramuscular/intravenous Injections:
For intramuscular
injection: 250 mg or 500 mg Axon should be dissolved
in 2 ml of 1% Lidocaine Injection USP or 1 g Axon in
3.5 ml of 1% Lidocaine Injection USP. For intravenous injection:
250 mg or 500 mg Axon should be dissolved in 5 ml of
Water for Injection BP or 1 g Axon in 10 ml of Water
for Injection BP. The injection should be administered over
2-4 minutes, directly into the vein or via the tubing of an
intravenous infusion. The use of freshly reconstituted solution
is recommended. However, it maintains potency for at least 6
hours at room temperature or 24 hours at 50 C.
Contraindications:
Ceftriaxone should
not be given to patients with a history of hypersensitivity
to cephalosporin antibiotics.
Precaution:
Its safety in human
pregnancy has not been established. Therefore it should not
be used in pregnancy unless absolutely indicated. Only minimal
amount of Ceftriaxone is excreted in breast milk, so mother-receiving
Ceftriaxone should not breast-feed. In severe renal impairment
accompanied by hepatic insufficiency, dosage reduction is required.
Adverse Reactions:
Ceftriaxone is
generally well tolerated. A few side effects such as gastro-intestinal
effects including diarrhoea, nausea and vomiting, stomatitis
& glossitis; cutaneous reactions including rash, pruritus,
urticaria, oedema & erythema multiforme; hematologic reactions
including eosinophilia, thrombocytopenia, leucopenia, anemia,
and neutropenia; hepatic reactions including elevations of SGOT
or SGPT, bilirubinemia; CNS reactions including headache, hyperactivity,
nervousness, sleep disturbances, confusion, hypertonia and dizziness
were reported. Local phlebitis occurs rarely following intravenous
administration but can be minimized by slow injections over
2-4 minutes.
Drug Interaction:
No drug interactions
have been observed with diuretics or with aminoglycosides.
Storage:
Store below 300
C · Protect from light · Keep out of the reach of children.
Incompatibilities:
The admixture of
beta-lactam antibacterials (penicillins and cephalosporins)
and aminoglycosides may result in substantial mutual inactivation.
If they are administered concurrently, they should be administered
in separate sites. Do not mix them in the same intravenous
bag or bottle.
Packing:
Axon is
supplied as sterile powder in glass vial.
Axon 250
mg IM Injection: Combipack of 1 vial containing 250 mg Ceftriaxone
(as sterile Ceftriaxone Sodium USP) and 1 ampoule of 2 ml 1%
Lidocaine Injection USP.
Axon 250
mg IV Injection: Combipack of 1 vial containing 250 mg Ceftriaxone
(as sterile Ceftriaxone Sodium USP) and 1 ampoule of 5 ml Water
for Injection BP.
Axon 500
mg IM Injection: Combipack of 1 vial containing 500 mg Ceftriaxone
(as sterile Ceftriaxone Sodium USP) and 1 ampoule of 2 ml 1%
Lidocaine Injection USP.
Axon 500
mg IV Injection: Combipack of 1 vial containing 500 mg Ceftriaxone
(as sterile Ceftriaxone Sodium USP) and 1 ampoule of 5 ml Water
for Injection BP.
Axon 1g
IM Injection: Combipack of 1 vial containing 1g Ceftriaxone
(as sterile Ceftriaxone Sodium USP) and 1 ampoule of 3.5 ml
1% Lidocaine Injection USP.
Axon 1g
IV Injection: Combipack of 1 vial containing 1g Ceftriaxone
(as sterile Ceftriaxone Sodium USP) and 1 ampoule of 10 ml Water
for Injection BP.
Axon 2g IV Injection: Box of 1 vial containing 2g Ceftriaxone (as sterile Ceftrixone Sodium USP) and 2 ampules of 10 ml water for injection BP.
|